BACKGROUND: The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of immediate versus deferred ART in patients with HIV-associated tuberculous meningitis to determine whether immediate ART reduced the risk of death. Antiretroviral drugs (zidovudine, lamivudine, and efavirenz) were started either at study entry or 2 months after randomization. All patients were treated with standard antituberculosis treatment, adjunctive dexamethasone, and prophylactic co-trimoxazole and were followed up for 12 months. We conducted intention-to-treat, per-protocol, and prespecified subgroup analyses. RESULTS: A total of 253 patients were randomized, 127 in the immediate ART group and 126 in the deferred ART group; 76 and 70 patients died within 9 months in the immediate and deferred ART groups, respectively. Immediate ART was not significantly associated with 9-month mortality (hazard ratio [HR], 1.12; 95% confidence interval [CI], .81-1.55; P = .50) or the time to new AIDS events or death (HR, 1.16; 95% CI, .87-1.55; P = .31). The percentage of patients with severe (grade 3 or 4) adverse events was high in both arms (90% in the immediate ART group and 89% in the deferred ART group; P = .84), but there were significantly more grade 4 adverse events in the immediate ART arm (102 in the immediate ART group vs 87 in the deferred ART group; P = .04). CONCLUSIONS: Immediate ART initiation does not improve outcome in patients presenting with HIV-associated tuberculous meningitis. There were significantly more grade 4 adverse events in the immediate ART arm, supporting delayed initiation of ART in HIV-associated tuberculous meningitis. Clinical Trials Registration. ISRCTN63659091.
RCT Entities:
BACKGROUND: The optimal time to initiate antiretroviral therapy (ART) in human immunodeficiency virus (HIV)-associated tuberculous meningitis is unknown. METHODS: We conducted a randomized, double-blind, placebo-controlled trial of immediate versus deferred ART in patients with HIV-associated tuberculous meningitis to determine whether immediate ART reduced the risk of death. Antiretroviral drugs (zidovudine, lamivudine, and efavirenz) were started either at study entry or 2 months after randomization. All patients were treated with standard antituberculosis treatment, adjunctive dexamethasone, and prophylactic co-trimoxazole and were followed up for 12 months. We conducted intention-to-treat, per-protocol, and prespecified subgroup analyses. RESULTS: A total of 253 patients were randomized, 127 in the immediate ART group and 126 in the deferred ART group; 76 and 70 patients died within 9 months in the immediate and deferred ART groups, respectively. Immediate ART was not significantly associated with 9-month mortality (hazard ratio [HR], 1.12; 95% confidence interval [CI], .81-1.55; P = .50) or the time to new AIDS events or death (HR, 1.16; 95% CI, .87-1.55; P = .31). The percentage of patients with severe (grade 3 or 4) adverse events was high in both arms (90% in the immediate ART group and 89% in the deferred ART group; P = .84), but there were significantly more grade 4 adverse events in the immediate ART arm (102 in the immediate ART group vs 87 in the deferred ART group; P = .04). CONCLUSIONS: Immediate ART initiation does not improve outcome in patients presenting with HIV-associated tuberculous meningitis. There were significantly more grade 4 adverse events in the immediate ART arm, supporting delayed initiation of ART in HIV-associated tuberculous meningitis. Clinical Trials Registration. ISRCTN63659091.
Authors: Gillian L Dean; Simon G Edwards; Natalie J Ives; Gail Matthews; Emma F Fox; Lesley Navaratne; Martin Fisher; Graham P Taylor; Rob Miller; Chris B Taylor; Annemiek de Ruiter; Anton L Pozniak Journal: AIDS Date: 2002-01-04 Impact factor: 4.177
Authors: Guy E Thwaites; Duc Bang Nguyen; Huy Dung Nguyen; Thi Quy Hoang; Thi Tuong Oanh Do; Thi Cam Thoa Nguyen; Quang Hien Nguyen; Tri Thuc Nguyen; Ngoc Hai Nguyen; Thi Ngoc Lan Nguyen; Ngoc Lan Nguyen; Hong Duc Nguyen; Ngoc Tuan Vu; Huu Hiep Cao; Thi Hong Chau Tran; Phuong Mai Pham; Thi Dung Nguyen; Kasia Stepniewska; Nicholas J White; Tinh Hien Tran; Jeremy J Farrar Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Azure T Makadzange; Chiratidzo E Ndhlovu; Kudakwashe Takarinda; Michael Reid; Magna Kurangwa; Philimon Gona; James G Hakim Journal: Clin Infect Dis Date: 2010-06-01 Impact factor: 9.079
Authors: J Berenguer; S Moreno; F Laguna; T Vicente; M Adrados; A Ortega; J González-LaHoz; E Bouza Journal: N Engl J Med Date: 1992-03-05 Impact factor: 91.245
Authors: M Estee Torok; Tran Thi Hong Chau; Pham Phuong Mai; Nguyen Duy Phong; Nguyen Thi Dung; Ly Van Chuong; Sue J Lee; M Caws; Menno D de Jong; Tran Tinh Hien; Jeremy J Farrar Journal: PLoS One Date: 2008-03-19 Impact factor: 3.240
Authors: Satish Gopal; Monita R Patel; Chad J Achenbach; Elizabeth L Yanik; Stephen R Cole; Sonia Napravnik; Greer A Burkholder; W Christopher Mathews; Benigno Rodriguez; Steven G Deeks; Kenneth H Mayer; Richard D Moore; Mari M Kitahata; Kristy L Richards; Joseph J Eron Journal: Clin Infect Dis Date: 2014-04-21 Impact factor: 9.079